UCB Archives - Page 4 of 6 -

Amgen and UCB have suffered another setback as they try to build momentum for Evenity, their new antibody

CHMP says no to Amgen’s osteoporosis drug Evenity

https://pharmaphorum.com/news/chmp-says-no-to-amgens-osteoporosis-drug-evenity/

Market Access/ News/ News/ Top stories

At long last, Amgen/UCB score FDA okay for Evenity

Phil Taylor Amgen, Evenity, osteoporosis, UCB 0 Comment

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down

At long last, Amgen/UCB score FDA okay for Evenity

https://pharmaphorum.com/news/at-long-last-amgen-ucb-score-fda-okay-for-evenity/

Patients/ Views & Analysis/ Views and analysis

Success comes from listening to and working with patients

Amanda Barrell Parkinson's, patient centricity, patient voice, UCB 0 Comment

With the current mainstay of Parkinson’s treatment being more than 50 years old and doing nothing to slow

Success comes from listening to and working with patients

https://pharmaphorum.com/views-analysis-patients/success-comes-from-listening-to-and-working-with-patients/

News/ News/ R&D

UCB joins with UK charity to research new epilepsy drugs

Richard Staines epilepsy, neurology, R&D, UCB 0 Comment

Belgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for

UCB joins with UK charity to research new epilepsy drugs

https://pharmaphorum.com/news/ucb-joins-with-uk-charity-to-research-new-epilepsy-drugs/

News

Japan approves Amgen’s osteoporosis drug

Richard Staines Amgen, osteoporosis, UCB 0 Comment

Amgen’s osteoporosis bone-forming drug Evenity (romosozumab) has been approved in Japan, ahead of a crunch review by advisers

Japan approves Amgen’s osteoporosis drug

https://pharmaphorum.com/news/japan-approves-amgens-osteoporosis-drug/

Market Access/ News/ News

NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasis

Richard Staines Almirall, dermatology, NICE, psoriasis, UCB 0 Comment

NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but

NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasis

https://pharmaphorum.com/news/nice-okays-ucbs-cimzia-nixes-almirall-ilumetri-in-psoriasis/

News/ Top stories

UCB, Roche, and IQVIA take lead in UK life sciences investment

Richard Staines IQVIA, R&D, Roche, UCB 0 Comment

Pharma giant UCB is to invest around £1 billion in the UK as part of a second life

UCB, Roche, and IQVIA take lead in UK life sciences investment

https://pharmaphorum.com/news/ucb-roche-and-iqvia-take-lead-in-uk-life-sciences-investment/

News/ News/ Sales and Marketing

Amgen and UCB re-file Evenity for US approval

Piotr Wnuk Amgen, Evenity, fda, monoclonal antibody, osteoporosis, UCB 0 Comment

Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that

Amgen and UCB re-file Evenity for US approval

https://pharmaphorum.com/news/amgen-ucb-evenity-fda-filing/

Market Access/ News/ News

FDA approves UCB’s Cimzia in plaque psoriasis

Linda Banks Cimzia, dermatology, immuno-dermatology, psoriasis, skin condition, UCB 0 Comment

The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis

FDA approves UCB’s Cimzia in plaque psoriasis

https://pharmaphorum.com/news/fda-ucbs-cimzia-plaque-psoriasis/

Trending

UCB

Login